MNMD Live signals | Maximize Profits with Getagraph.com

BUY 100287 min ago

@ $4.45

Issued: 14 Feb 2024 @ 12:00

Return: 99.32%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -4.40 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology...

Stats
Today's Volume	1.20M
Average Volume	2.26M
Market Cap	625.34M
EPS	$0 ( 2024-02-28 )
Next earnings date	( $-0.660 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.64
ATR14	$0.0200 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Greenway Schond L.	Sell	5 560	Common Shares
2024-03-25	Karlin Dan	Sell	6 578	Common Shares
2024-03-25	Barrow Robert	Sell	16 519	Common Shares
2024-02-27	Wernli Miri Halperin	Buy	125 000	Stock Option (Right to Buy)
2024-02-27	Greenway Schond L.	Buy	150 000	Stock Option (Right to Buy)

INSIDER POWER
90.00
Last 96 transactions
Buy: 11 612 599 \| Sell: 348 471

Volume Correlation

Long: -0.29 (neutral)

Short: -1.00 (very strong negative)

Signal:(26.356) Possible Trading Opportunity Present (swing)

Mind Medicine (MindMed) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mind Medicine (MindMed) Correlation - Currency/Commodity

-0.37
( neutral )

0.64
( weak )

0.00
( neutral )

-0.84
( strong negative )

-0.39
( neutral )

0.67
( moderate )

Mind Medicine (MindMed) Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-3.16M (0.00 %)
EPS:	$-2.44

Q4	2023
Revenue:	$0
Gross Profit:	$-790 000 (0.00 %)
EPS:	$-0.590

Q3	2023
Revenue:	$0
Gross Profit:	$-800 000 (0.00 %)
EPS:	$-0.450

Q2	2023
Revenue:	$0
Gross Profit:	$-814 000 (0.00 %)
EPS:	$-0.760

Financial Reports:

No articles found.

Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.